US Patent

US10870676 — Antisense nucleic acids

Method of Use · Assigned to Nippon Shinyaku Co Ltd · Expires 2031-08-31 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an oligomer and pharmaceutical composition that cause skipping of the 53rd exon in the human dystrophin gene.

USPTO Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

Drugs covered by this patent

Viltepso (VILTOLARSEN) · Nippon Shinyaku

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3039`	—	Viltepso

Patent Metadata

Patent number: US10870676
Jurisdiction: US
Classification: Method of Use
Expires: 2031-08-31
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Nippon Shinyaku Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.